(Alliance News) - PureTech Health PLC said Tuesday its affiliate Gelesis will partner with Ro, a US telehealth provider, to support US commercialization of weight-management treatment Plenity.
The biotechnology company said that Plenity will be the first US Food & Drug Administration-cleared weight management aid and first primary care product to launch with both traditional healthcare provider and 'telehealth' services, making Plenity available to patients nationwide.
PureTech said Gelesis retains worldwide sales and marketing rights for Plenity and, since US FDA clearance, has secured close to USD100 million in new capital to support the US commercial launch.
Ro provides a personalized end-to-end telehealth experience from medical diagnosis to the home delivery of prescription and over-the-counter products, the company said.
Plenity will be the only weight management treatment available through Ro's digital clinics as it expands to treat new conditions on its platform, PureTech said.
Eric Elenko, chief innovation officer at PureTech, said: "We are pleased with the progress Gelesis has made towards the broad commercialisation of Plenity, and this partnership with Ro underscores the Gelesis commitment to innovation in healthcare."
"Through the company's multipronged commercial strategy, Gelesis aims to empower individuals to access care where they are most comfortable - either through traditional providers or via a telehealth experience," Elenko said.
PureTech shares were down 0.4% in London at 275.00 pence each late on Tuesday.
By Loreta Juodagalvyte; loretajuodagalvyte@alliancenews.com
Copyright 2019 Alliance News Limited. All Rights Reserved.
PureTech (PRTC)